LADIES WHO ROCK FOR A CAUSE FOUNDATION PRESENTS THEIR 2021 GLOBAL MUSIC FESTIVAL VIRTUALLY ON APRIL 18TH AT 8:00 pm EDT
Share Article PHILADELPHIA (PRWEB) April 12, 2021 The Ladies Who Rock For A Cause® Foundation is excited to bring their annual music festival to the world virtually on April 18, 2021, at 8:00 pm EDT. The LADIES WHO ROCK FOR A CAUSE leverages the unifying power of music to help those in need. This festival, which will highlight female musicians from around the world, is set to raise awareness in the fight against Ataxia. Ataxia is a rare and debilitating neurological disease with no cure. A portion of the proceeds will benefit the National Ataxia Foundation in that fight, and an individual in need.
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
- NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020
- Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers
- Regulatory filing for rimegepant in Europe submitted and accepted for review by European Medicines Agency for dual-acting (acute and prevention) indication for treatment of migraine
- Life-cycle management studies for CGRP-antagonist program underway, including initiation of Phase 4 study of NURTEC ODT in pediatric migraine
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Critical Path Institute and global partners establish Ataxia Consortium
Critical Path Institute (C-Path) today announced the launch of the Critical Path to Therapeutics for the Ataxias (CPTA) Consortium, a public-private partnership focused on optimizing clinical trials for inherited ataxias.
CPTA is a collaborative effort between C-Path, Ataxia Global Initiative, the National Ataxia Foundation, Ataxia UK and key partners in the industry and academic research communities, including Biohaven Pharmaceuticals, Ionis Pharmaceuticals, Roche Pharmaceuticals, Servier Group, Triplet Therapeutics, uniQure, and Vico Therapeutics. CPTA s mission is to bring together experts from across different fields of ataxia research, advocacy and medical product development to create regulatory tools and strategies that will catalyze the development of therapeutics for the ataxias, said Jane Larkindale, D.Phil., Executive Director of the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA
C-Path and Global Partners launch Ataxia Consortium eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.